glp 1 hba1c reduction View of GLP-1 receptor agonists in type 2 diabetes - NICE guidelines versus clinical practice Real-World HbA1c Changes Among Type

Gastroenterology 142:4654.e42

HOLST: The Gila monster, it was actually a great inspiration, so the study where we demonstrated the effect in diabetes was from 1993, and that's what convinced at least some of the pharmaceutical companies, and certainly Novo Nordisk in Denmark, that perhaps it was worthwhile working with this peptide, and that's why, that's when they started developing what later became liraglutide or Victoza

Together, they prove that GLP-1 therapy can induce a state of "metabolic neuropathy" even in patients with normal blood sugar

Compounded medications are not FDA-approved as finished products, but they are prepared by licensed 503A compounding pharmacies regulated by state boards and the FDA

BCBS is a federation of 33 independent companies, and each sets its own drug coverage policies